BR112021020402A2 - Moduladores da via de resposta ao estresse integrada - Google Patents

Moduladores da via de resposta ao estresse integrada

Info

Publication number
BR112021020402A2
BR112021020402A2 BR112021020402A BR112021020402A BR112021020402A2 BR 112021020402 A2 BR112021020402 A2 BR 112021020402A2 BR 112021020402 A BR112021020402 A BR 112021020402A BR 112021020402 A BR112021020402 A BR 112021020402A BR 112021020402 A2 BR112021020402 A2 BR 112021020402A2
Authority
BR
Brazil
Prior art keywords
stress response
modulators
integrated stress
response pathway
compounds
Prior art date
Application number
BR112021020402A
Other languages
English (en)
Inventor
Francis Palmer Christopher
John Brown Christopher
Simon Walter Daryl
Holly Atton
Irena Reboule
Lindsay Carr James
Jonathan Shine
Marissa Flower
Michael Corr
Mohamad Sabbah
Scott Sadler
Serge Convers-Reignier
Original Assignee
Evotec Int Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evotec Int Gmbh filed Critical Evotec Int Gmbh
Publication of BR112021020402A2 publication Critical patent/BR112021020402A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

moduladores da via de resposta ao estresse integrada. a presente invenção refere-se a compostos de fórmula (i) ou sais farmaceuticamente aceitáveis, solvatos, hidratos, tautômeros ou estereoisômeros dos mesmos, em que r1, r2, r2a, r3, ra2, ra4, ra5, ra6, ra7, x1, x1a, a1 e a2 têm os significados como indicados na descrição e reivindicações. a invenção também se refere a composições farmacêuticas compreendendo os referidos compostos, seu uso como medicamento e a um método para tratamento e prevenção de uma ou mais doenças ou distúrbios associados com resposta ao estresse integrada.
BR112021020402A 2019-04-23 2020-04-22 Moduladores da via de resposta ao estresse integrada BR112021020402A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19170504 2019-04-23
EP19216875 2019-12-17
PCT/EP2020/061150 WO2020216766A1 (en) 2019-04-23 2020-04-22 Modulators of the integrated stress response pathway

Publications (1)

Publication Number Publication Date
BR112021020402A2 true BR112021020402A2 (pt) 2021-12-07

Family

ID=70289816

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021020402A BR112021020402A2 (pt) 2019-04-23 2020-04-22 Moduladores da via de resposta ao estresse integrada

Country Status (15)

Country Link
US (1) US20220227747A1 (pt)
EP (1) EP3959198A1 (pt)
JP (1) JP2022530049A (pt)
KR (1) KR20220004105A (pt)
CN (1) CN113993850B (pt)
AU (1) AU2020261234A1 (pt)
BR (1) BR112021020402A2 (pt)
CA (1) CA3137213A1 (pt)
CL (1) CL2021002772A1 (pt)
CO (1) CO2021014292A2 (pt)
IL (1) IL287379A (pt)
MX (1) MX2021012903A (pt)
PE (1) PE20220961A1 (pt)
SG (1) SG11202111119PA (pt)
WO (1) WO2020216766A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3085132A1 (en) 2017-12-13 2019-06-20 Praxis Biotech LLC Inhibitors of integrated stress response pathway
BR112020023115A2 (pt) 2018-06-05 2021-02-02 Praxis Biotech LLC inibidores da via integrada de resposta a tensão
EP3982965A4 (en) 2019-06-12 2023-01-25 Praxis Biotech LLC INTEGRATED STRESS RESPONSE PATHWAY MODULATORS
WO2021165927A1 (en) * 2020-02-21 2021-08-26 Wockhardt Bio Ag 2-cyanopyrroldines, -piperidines or -dazepines as hyperglycemic agents
EP4117780A1 (en) 2020-03-11 2023-01-18 Evotec International GmbH Modulators of the integrated stress response pathway
AU2021363616A1 (en) 2020-10-22 2023-06-22 Evotec International Gmbh Modulators of the integrated stress response pathway
KR20230110511A (ko) 2020-10-22 2023-07-24 에보텍 인터내셔널 게엠베하 통합 스트레스 반응 경로의 조절제
JP2023546225A (ja) 2020-10-22 2023-11-01 エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 統合ストレス応答経路のモジュレーター
TW202304421A (zh) * 2021-04-02 2023-02-01 美商普拉西斯生物技術有限責任公司 整合應激路徑之調節劑

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2904794C (en) 2013-03-15 2021-11-23 Peter Walter Modulators of the eif2alpha pathway
AU2015283671B2 (en) * 2014-07-04 2018-07-05 Lupin Limited Quinolizinone derivatives as Pl3K inhibitors
WO2017046739A1 (en) * 2015-09-15 2017-03-23 Glaxosmithkline Intellectual Property (No.2) Limited Imidazolidinone derivatives as inhibitors of perk
TW201722957A (zh) * 2015-09-15 2017-07-01 葛蘭素史克智慧財產（第二）有限公司 化學化合物
TW201808903A (zh) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TW201808888A (zh) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TW201808914A (zh) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TWI763668B (zh) 2016-05-05 2022-05-11 美商嘉來克生命科學有限責任公司 整合應激途徑之調節劑
CA3026983A1 (en) * 2016-06-08 2017-12-14 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
WO2017212425A1 (en) * 2016-06-08 2017-12-14 Glaxosmithkline Intellectual Property Development Limited Chemical compounds as atf4 pathway inhibitors
WO2018225093A1 (en) 2017-06-07 2018-12-13 Glaxosmithkline Intellectual Property Development Limited Chemical compounds as atf4 pathway inhibitors
BR112020000122A2 (pt) 2017-07-03 2020-07-07 Glaxosmithkline Intellectual Property Development Limited derivados da n-(3-(2-(4-clorofenóxi)acetamido)biciclo[1.1.1] pentan-1-il)-2-ciclobutano-1-carboxamida e compostos relacionados como inibidores do atf4 para tratamento contra o câncer e outras doenças
BR112020000086A2 (pt) 2017-07-03 2020-07-07 Glaxosmithkline Intellectual Property Development Limited derivados de 2-(4-clorofenóxi)-n-((1-(2-(4-clorofenóxi) etinazetidin-3-il) metil) acetamida e compostos relacionados como inibidores de atf4 para tratamento de câncer e outras doenças
AU2018313850B2 (en) 2017-08-09 2022-12-22 Denali Therapeutics Inc. Compounds, compositions and methods
SI3676297T1 (sl) 2017-09-01 2023-12-29 Denali Therapeutics Inc. Spojine, sestavki in postopki
MX2020004537A (es) 2017-11-02 2020-10-05 Calico Life Sciences Llc Moduladores de la vía integrada del estrés.
AU2018358160B2 (en) 2017-11-02 2023-03-16 Abbvie Inc. Modulators of the integrated stress pathway
UY37957A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
UY37956A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
US20210205277A1 (en) 2017-11-02 2021-07-08 Calico Life Sciences Llc Modulators of the integrated stress pathway
CA3080948A1 (en) 2017-11-02 2019-05-09 Calico Life Sciences Llc Modulators of the integrated stress pathway
WO2019090074A1 (en) 2017-11-02 2019-05-09 Calico Life Sciences Llc Modulators of the integrated stress pathway
IL274406B2 (en) 2017-11-02 2024-04-01 Calico Life Sciences Llc Combined pressure pathway modulators
UY37958A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
CA3085132A1 (en) 2017-12-13 2019-06-20 Praxis Biotech LLC Inhibitors of integrated stress response pathway
US20210130308A1 (en) * 2018-03-23 2021-05-06 Denali Therapeutics Inc. Modulators of eukaryotic initiation factor 2
WO2019193541A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors
WO2019193540A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Heteroaryl derivatives of formula (i) as atf4 inhibitors

Also Published As

Publication number Publication date
CN113993850B (zh) 2024-03-29
CO2021014292A2 (es) 2022-04-29
WO2020216766A1 (en) 2020-10-29
AU2020261234A1 (en) 2021-11-11
EP3959198A1 (en) 2022-03-02
US20220227747A1 (en) 2022-07-21
CA3137213A1 (en) 2020-10-29
CN113993850A (zh) 2022-01-28
SG11202111119PA (en) 2021-11-29
KR20220004105A (ko) 2022-01-11
JP2022530049A (ja) 2022-06-27
MX2021012903A (es) 2022-01-18
PE20220961A1 (es) 2022-06-10
IL287379A (en) 2021-12-01
CL2021002772A1 (es) 2022-07-29

Similar Documents

Publication Publication Date Title
BR112021020402A2 (pt) Moduladores da via de resposta ao estresse integrada
BR112021020106A2 (pt) Moduladores da via de resposta ao estresse inte-grado
BR112022012643A2 (pt) Moduladores da via de resposta ao estresse integrada
BR112022014706A2 (pt) Moduladores da via de resposta integrada ao estresse
Vucicevic et al. Autophagy inhibition uncovers the neurotoxic action of the antipsychotic drug olanzapine
BR112018015273A2 (pt) derivados de benzimidazol como moduladores de ror-gama
BR112019012217A2 (pt) compostos de amino-triazolopiridina e seu uso no tratamento de câncer
BR112017026159A2 (pt) inibidores heterocíclicos de erk1 e erk2 e seu uso no tratamento de câncer
BR112022000019A2 (pt) Composto da fórmula, composição farmacêutica e método de tratamento de câncer
BR112017007460A2 (pt) inibidores de di-hidropirrolopiridina de ror-gama
BR112016016844A2 (pt) Compostos heterocíclicos
BR112016015983A2 (pt) Compostos de indazol como inibidores de irak4, seus usos, e composição farmacêutica
CO2019010078A2 (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
BR112018068532A2 (pt) combinações de inibidores de lsd1 para o tratamento de malignidades hematológicas
BR112014016157A8 (pt) derivados heterobicíclicos como inibidores de vhc
BR112017009012A2 (pt) derivados de anel benzo de seis membros como inibidor de dpp-4 e seu uso
BR112021023770A2 (pt) Compostos de derivado de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos
BR112021025764A2 (pt) Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo
BR112021023927A2 (pt) Composto, e, composição farmacêutica
BR112021024948A2 (pt) Moduladores de próxima geração de estimulador de genes de interferon (sting)
BR112022024840A2 (pt) Combinação de alcaftadina e um corticosteroide
BR112022020609A2 (pt) Composição farmacêutica para administração oral que compreende derivado de aminopirimidina ou sal, hidrato ou solvato farmaceuticamente aceitável do mesmo
BR112022001393A2 (pt) Forma cristalina do inibidor de atr e seu uso
DOP2018000197A (es) Compuestos de cinnolin-4-amina y su uso en el tratamiento del cáncer
UY38488A (es) Derivados de pirazol y su uso en medicina